Prof. Ofer Mandelboim
Before becoming an IMRIC researcher, I studied at the Weitzman Institute and did my post doctoral work at Harvard. I was delighted to be accepted at Hebrew University. I enjoy doing research, and at IMRIC, I am working with a team of outstanding students in collaboration with Dr. Plummer and his team to isolate the NK cells that target AIDS and prevent its spread.
But it goes beyond that.
This IMRIC collaboration is leading us to make some important discoveries in other areas on the way to finding a cure for AIDS. Once we learn how the process works, we can start isolating virus-specific NK cells to target a whole range of viruses, like influenza, and prevent their spread.
1995-1999: Post-doctoral research fellow with Prof. Jack L Strominger, Department of Molecular and Cellular Biology, Harvard University, USA.
1996: Ph.D. Degree, Suma cum laude. Title: Isolation and characterization of tumor associated antigen (TAA) peptides from mouse lung carcinoma. Supervisors: Prof. Lea Eisenbach and Prof. Gideon Berke.
1991-1995: Weizmann Institute of Science, Rehovot, Israel.
1991: M.Sc. Degree Title: Reduced tumorgenicity and metastatic spread of 3LL cells transfected by two H-2K genes. Supervisors: Prof. Lea Eisenbach and Prof. Michael Feldman.
1988-1990: The Weizmann Institute of Science, Rehovot, Israel.
1985-1988: Bar-Ilan University, Ramat-Gan, Israel, Faculty of Life Science. B.A. Degree 1989, Cum laude.
Dr. Frank Plummer's team at the University of Manitoba and Prof. Ofer Mandelboim's team at IMRIC have completed their first year of collaborative research. Researchers from both Winnipeg and Jerusalem travelled to Kenya, and their work in the field showed that NK cells do play a role in building resistance to infectious diseases such as HIV.
Congratulations To Our 6 researchers On Receiving The Prestigious European Research Council (ERC) 2012 Grant!
6 IMRIC Researchers Are Awarded 2012 Grants From The European Research Council:
As a result of a Massachusetts family’s desire to advance both diabetes research and Israeli scientific innovation, five Israeli researchers each will be receiving up to $130,000 per year for up to three years toward investigations into Type 1 diabetes
Hebrew University IMRIC Researchers Suggest Boosting Body’s Natural Flu Killers As Way To Offset Virus Mutation Problem
A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have shown recently that another, more promising, approach is to focus on improving drugs that boost the body’s natural flu killer system.
Hebrew University immunologist Professor Ofer Mandelboim won The Hebrew University’s prestigious Kaye Innovation Award for his research underlying BL-9020, for the treatment of Type 1 diabetes.